Rani Therapeutics (NASDAQ: RANI) — Perfil da empresa, notícias e dados financeiros
Rani Therapeutics develops oral biologics using the RaniPill™ capsule, targeting patient-friendly drug delivery methods.

Rani Therapeutics
Rani Therapeutics (NASDAQ:RANI) focuses on the development of oral biologics that aim to replace traditional subcutaneous or intravenous injections, addressing a major market need for more patient-friendly drug delivery methods. Their innovative technology, known as the RaniPill™ capsule, is designed to navigate through the stomach and release its payload directly into the intestine, with the aim of achieving similar levels of drug absorption as injections but without the needles. Projects primarily revolve around applying this technology to a range of biologic drugs, including those for diabetes, arthritis, and other chronic conditions. Objectives include advancing these projects through clinical trials, achieving regulatory approvals, and ultimately commercializing their platform to improve patient outcomes and adherence for biologic treatments.
Resumo
Operações
Produtos e/ou serviços de Rani Therapeutics
- Development of the RaniPill™ capsule, an oral delivery mechanism designed to replace subcutaneous or intravenous injections for various drugs.
- Partnership projects for the RaniPill platform to deliver biologics and peptides orally, including collaborations with major pharmaceutical companies.
- Clinical trials for the RaniPill capsule in target therapies such as the treatment of chronic diseases, highlighting its potential in improving patient compliance and convenience.
- Research into expanding the application of the RaniPill technology beyond its current capabilities to include more complex biologics and potentially vaccines.
- Initiatives to enhance the formulation and delivery technology within the RaniPill capsules, aiming to increase the bioavailability and efficacy of orally administered drugs.
- Outreach and educational programs aimed at healthcare professionals to increase awareness and understanding of the benefits of oral biologic delivery systems.
equipe executiva do Rani Therapeutics
- Mir A. ImranExecutive Chairman
- Talat ImranCEO & Director
- Kate McKinleyChief Business Officer
- Nicholas MaestasChief Financial Officer
- Alireza JavadiChief Technical Officer
- Mir HashimChief Scientific Officer
- Bella VazquezSenior Vice President of People & Administrative Services
- Jesper HoeilandHead of Strategy
- Arvinder DhallaVice President of Clinical Development
Principais indicadores financeiros
Resultados divulgados pela Rani Therapeutics, em USD.
- Cap. de mercado
- 85,6 mi
- Receita (TTM)
- 4,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,6 mi | -38,3 mi | -29,7 mi | |
| 1 mi | -53,3 mi | -30 mi | |
| 0 | -66,1 mi | -34 mi | |
| 0 | -63,5 mi | -30,6 mi |